Statins can reduce sepsis deaths, study suggests
People who are critically ill with sepsis may be more likely to survive if they are given statins, a new study suggests.
Researchers wanted to explore whether the cholesterol-busting drugs may bring additional benefits for patients.
The new study examined information on sepsis patients who received statins during a stint in intensive care and compared it with patients in a similar situation who did not receive statins.
Sepsis can be life-threatening, but knowing the signs can save lives.
Symptoms differ in adults, children, & infants under 5.
Learn more: https://t.co/kvKqriFS6D pic.twitter.com/e6D6dmIJSD
— The UK Sepsis Trust (@UKSepsisTrust) January 7, 2025
Some 14.3% of 6,000 sepsis patients who were given statins died within 28 days.
This is compared with 23.4% of 6,000 patients who did not receive statin therapy.
The research team from China said that this equates to a 39% reduced risk of death within a month.
The research, based on data from thousands of patients at a hospital in Israel between 2008 and 2019, also found that 7.4% of statin patients died while in the intensive care unit compared with 13.6% of those who did not receive statins.
And during their overall hospital stay, some 11.5% of sepsis patients who were given statins died, compared with 19.1% of sepsis patients who did not take statins.
However, it appeared that those who were not prescribed statins had a slightly shorter hospital stay compared with those who did receive them – an average of eight days compared with almost 10 days.
'We found that statin users exhibited decreased 28-day all-cause mortality,' the authors wrote in the journal Frontiers in Immunology.
Sepsis is a life-threatening reaction to an infection that occurs when the immune system overreacts and starts to damage the body's tissues and organs.
In the UK, 245,000 people are affected by sepsis every year.
UK sepsis experts said that 'anything which might reduce the burden of a condition which claims one in five lives worldwide needs to be rigorously explored' as they called for larger trials to confirm the findings.
Statins are known as cholesterol-busting drugs because they can help lower the level of low-density lipoprotein (LDL) cholesterol in the blood.
But experts said that they also have other benefits, including reducing inflammation and antibacterial effects.
The research team called for larger trials to confirm their findings.
'Our large, matched cohort study found that treatment with statins was associated with a 39% lower death rate for critically ill patients with sepsis, when measured over 28 days after hospital admission,' said Dr Caifeng Li, the study's corresponding author and an associate professor at Tianjin Medical University General Hospital in China.
'These results strongly suggest that statins may provide a protective effect and improve clinical outcomes for patients with sepsis.'
Commenting on the study, Dr Ron Daniels, founder and chief executive of the UK Sepsis Trust, said: 'It has been known for some time that the anti-inflammatory properties of statins confer a survival benefit on those who take them if they develop sepsis.
'Whilst previous studies have failed to show a similar survival benefit in treating people with sepsis with statins, this new study supports calls for a large, multi-country, randomised control trial.
'Anything which might reduce the burden of a condition which claims one in five lives worldwide needs to be rigorously explored.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Health Line
an hour ago
- Health Line
What's the Life Expectancy for Parkinson's Disease?
Key takeaways At age 65, patients with Parkinson's disease have a life expectancy reduced by 6.7 years compared to those without the disease, while at age 85, the difference in life expectancy is 1.2 years. Severe clinical milestones that can impact survival include visual hallucinations, recurrent falls, dementia, and placement in a nursing home. Each milestone may double the risk of death during a 10-year period. Males with Parkinson's disease may experience a greater reduction in life expectancy than females, and those diagnosed before age 70 typically see a larger decrease in life expectancy compared to later diagnoses. If you or a loved one has received a diagnosis of Parkinson's, you may be wondering how the disease may progress over time. Parkinson's disease is a slow, progressive disease. This means that symptoms gradually worsen over time. While Parkinson's disease itself isn't fatal, related complications can reduce life expectancy. The individual outlook can vary based on the severity of Parkinson's disease, a person's overall health, and the type of Parkinson's disease they have. Research from 2020 suggests that at 65 years, the life expectancy of patients with Parkinson's was reduced by 6.7 years compared to that of people without Parkinson's disease. At 85, the difference in life expectancy was 1.2 years. Keep reading to learn more about the disease course and outlook with Parkinson's disease and the factors that may inform a doctor's prediction about a person's outlook. Factors that affect the outlook with Parkinson's disease Symptoms and complications can affect the outlook of a person with Parkinson's disease. Symptoms and severity Research from 2022 suggests that the presence of certain severe clinical milestones may predict a person's disease course with Parkinson's disease and increase the risk of death. Each milestone may double the risk of death during a 10-year period. These milestones include: visual hallucinations recurrent falls dementia placement in a nursing home Parkinson's and falls Falls are a common secondary symptom of Parkinson's disease. The risk of falling increases in stages 3 and is greater in stages 4 and 5. In these stages, you may not be able to stand or walk on your own. You'll also be prone to broken bones and concussions, and severe falls can be dangerous. Complications from a serious fall can reduce your life expectancy. Age Age is another factor in the diagnosis and outlook for Parkinson's disease. Most people will receive a diagnosis after 70. As you get older, you may be more prone to falls and more likely to develop certain diseases, even if you don't have Parkinson's disease. These risks can increase if you have Parkinson's. Research from 2020 suggests that people who receive a diagnosis before age 70 usually experience a greater reduction in life expectancy: In people at age 55: a 10.1-year reduction In people at age 65: a 6.7-year reduction In people at age 75: a 3.5-year reduction In people at age 85: a 1.2-year reduction Sex Research suggests that males with Parkinson's may have a greater reduction in life expectancy than females. Access to treatment Life expectancy has increased significantly due to advances in treatment. Medications and physical and occupational therapy are especially helpful in the earliest stages of Parkinson's. These treatments can improve your quality of life. Type of disease The type of parkinsonism can also impact a person's life expectancy, according to 2020 research. People with atypical parkinsonism, including Lewy body dementia, progressive supranuclear palsy, and multiple system atrophy, have increased mortality compared to people with typical Parkinson's disease and people without Parkinson's disease. Long-term outlook Early detection of Parkinson's disease is key to helping reduce complications that can negatively affect the outlook. If you suspect that you or a loved one may have Parkinson's disease, consult a doctor right away. Parkinson's symptoms and severity by stage Doctors classify Parkinson's disease into stages 1 to 5, with stage 5 being the most advanced. Advanced stages may increase the risk of health complications that can reduce life span. The symptoms of Parkinson's are gradual and are sometimes not noticeable in the early stages of the disease. They may include: tremors loss of balance slowing of movements spontaneous, uncontrollable movements Symptoms in later stages of Parkinson's may include: more frequent falls trouble dressing difficulty eating swallowing severe stiffness in your legs, which makes it impossible to stand or walk hallucinations or delusions cognitive changes (problems with planning, language, attention, or memory) dementia lightheadedness mood disorders loss of sense of smell or taste vision problems sleep disorders sexual problems As Parkinson's progresses to stages 3, 4, and 5, the risk of falling may increase, and motor balance may worsen. Pneumonia, particularly aspiration pneumonia, is the leading cause of death for people with Parkinson's, accounting for 70% of Parkinson's deaths. Aspiration pneumonia happens when you inhale food, stomach acid, or saliva into the lungs. As Parkinson's progresses, swallowing can become more difficult, causing food and liquid to enter the lungs. Treatment may help reduce symptoms. Frequently asked questions Why does it take so long for a diagnosis of Parkinson's disease? There is no definitive medical test that can be performed to diagnose Parkinson's disease. It's essentially a clinical diagnosis, meaning a doctor will make the diagnosis based on several clinical features seen. Symptoms of Parkinson's disease include tremor, slowness of movement, stiffness, and balance problems. However, the presentation and progression of these symptoms vary widely from person to person. The initial presentation is often subtle and may be similar to other conditions. Some people think their symptoms are due to normal aging, which may make them delay seeking medical attention. Another common finding in patients with Parkinson's disease is 'masked facies,' or an expressionless face, which often gets mistaken for depression. If there's concern that someone is developing Parkinson's disease, they should get a clinical exam from a neurologist to get a diagnosis. There is no definitive medical test that can be performed to diagnose Parkinson's disease. It's essentially a clinical diagnosis, meaning a doctor will make the diagnosis based on several clinical features seen. Symptoms of Parkinson's disease include tremor, slowness of movement, stiffness, and balance problems. However, the presentation and progression of these symptoms vary widely from person to person. The initial presentation is often subtle and may be similar to other conditions. Some people think their symptoms are due to normal aging, which may make them delay seeking medical attention. Another common finding in patients with Parkinson's disease is 'masked facies,' or an expressionless face, which often gets mistaken for depression. If there's concern that someone is developing Parkinson's disease, they should get a clinical exam from a neurologist to get a diagnosis. Is Parkinson's disease fatal? While Parkinson's disease is not fatal, it can cause complications that increase the risk of death. People with Parkinson's have a mortality rate 3 times that of people without Parkinson's. While Parkinson's disease is not fatal, it can cause complications that increase the risk of death. People with Parkinson's have a mortality rate 3 times that of people without Parkinson's. Can treatment help prevent Parkinson's disease complications? Parkinson's disease cannot be cured, but medications, supportive treatments, lifestyle changes, and even surgery can help manage your symptoms or delay more severe symptoms, especially if you start treatment early. This may reduce complications. Parkinson's disease cannot be cured, but medications, supportive treatments, lifestyle changes, and even surgery can help manage your symptoms or delay more severe symptoms, especially if you start treatment early. This may reduce complications.
Time Business News
2 hours ago
- Time Business News
SyntecBiofuel Plans to Open New Lab in Asia
Syntecbiofuel Strategic investment in microbial biofuel technology aims to accelerate Asia's clean energy transition and strengthen global supply chains SyntecBiofuel, a global leader in sustainable biofuel innovation, today announced the establishment of a new state-of-the-art research and development laboratory in Asia [location TBD, e.g., Singapore or South Korea]. This expansion underscores SyntecBiofuel's commitment to revolutionizing biofuel production through synthetic biology and scaling sustainable solutions tailored for the rapidly growing Asian market. The strategic move aligns with the region's accelerating focus on decarbonization and renewable energy adoption. The new lab will leverage Asia's abundant biomass feedstocks and foster collaboration with local academic institutions and industry partners to drive breakthroughs in microbial biofuel technology. 'Our mission is to bridge synthetic biology innovations with scalable biofuel solutions that meet global sustainability goals,' said [CEO Name], CEO of SyntecBiofuel. 'Asia's vibrant innovation ecosystem is pivotal in achieving net-zero targets worldwide, and this lab will serve as a catalyst for delivering affordable, carbon-neutral biofuels to one of the world's fastest-growing energy markets.' The lab's core research initiatives will focus on metabolic engineering, waste-to-fuel conversion technologies, and optimizing biofuel yield and efficiency. These efforts aim to reduce production costs and enable the deployment of sustainable aviation fuel (SAF) and bio-gasoline tailored for the Asian market. SyntecBiofuel plans to launch the facility by [expected opening date], with a hiring initiative to recruit leading scientists and engineers in bioenergy and synthetic biology. The company invites strategic partnerships with investors, policymakers, and green technology collaborators to accelerate the transition to a sustainable energy future. Founded in [Year], SyntecBiofuel is a UK-based clean technology company pioneering advanced biofuel solutions. Backed by multiple patents and successful commercial deployments, SyntecBiofuel delivers innovative, sustainable fuels that reduce carbon emissions and support the circular economy. Media Contact Get in Touch with SyntecBiofuel's Media Relations Team For all press inquiries, interview requests, or media partnerships, please contact: Follow Us Online Stay updated on the latest news, innovations, and events from SyntecBiofuel: TIME BUSINESS NEWS
Medscape
4 hours ago
- Medscape
Nefecon Shows IgAN Benefits Regardless of Baseline eGFR
Nefecon, an oral targeted-release formulation of budesonide that targets drug release into the distal ileum, provided significant improvements in the loss of kidney function in patients with immunoglobulin A nephropathy (IgAN) at 9 months, regardless of baseline estimated glomerular filtration rate (eGFR) status, according to a new subanalysis of the phase 3 NeflgArd study. METHODOLOGY: Patients in the NeflgArd study with primary IgAN were randomly assigned to one of two groups of 182 patients each to receive either treatment with 16 mg Nefecon or placebo daily, along with supportive care with renin-angiotensin system inhibition. This was followed by a 15-month off-drug observational period allowing for continued supportive care. For the subanalysis, the patients were further stratified on the basis of eGFR deciles in relation to the overall study population, with levels above and below 38, 43, 47, 51, 55, 60, 66, 72, and 82 mL/min/1.73 m 2 . . The median eGFR overall was 55.49 mL/min/1.73 m2 and was balanced across the Nefecon and placebo groups. TAKEAWAY: The relative benefit of Nefecon in terms of eGFR was seen across most deciles and timepoints and showed a generally greater benefit in higher baseline eGFR groups (above 72 mL/min/1.73 m 2 ). ). Furthermore, the relative urine protein-creatinine ratio benefit was observed from month 9 with Nefecon vs placebo regardless of baseline eGFR, with a continued reduction to month 12, followed by a maintained treatment benefit to month 24. The eGFR benefits with Nefecon over placebo were observed among patients within the upper and lower deciles over 2 years. eGFR showed a pronounced on-treatment benefit and a delay in decline during the observation period. IN PRACTICE: 'This NefIgArd subanalysis demonstrated that the efficacy of a 9-month Nefecon treatment course in reduction of proteinuria and preservation of kidney function was independent of baseline eGFR,' said first author Jonathan Barratt, MD, of the College of Life Sciences, University of Leicester, UK. 'So, we should be confident about treating people with Nefecon across the full range of eGFR in terms of the eGFR saving we're going to see, but also the proteinuria reduction,' he added. SOURCE: The findings were reported this week at the 62nd European Renal Association (ERA) Congress 2025. DISCLOSURES: The study was funded by Calliditas Therapeutics AB. Credit Lead image: Medscape Medscape Medical News © 2025 WebMD, LLC Cite this: Nefecon Shows IgAN Benefits Regardless of Baseline eGFR - Medscape - June 06, 2025.
